The effects of phenylephrine 2.5% versus phenylephrine 10% on pupillary dilation in patients with diabetes

J. S. Weiss, J. N. Weiss, David Greenfield

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Purpose: A prospective, double-blind study was conducted to compare the clinical efficacy of a combination of 1% tropicamide and 2.5% phenylephrine and a combination of 1% tropicamide and 10% phenylephrine for pupillary dilation in patients with diabetes. Methods: Either 2.5% phenylephrine in one eye and 10% phenylephrine in the other eye, 2.5% phenylephrine in both eyes, or 10% phenylephrine in both eyes was administered to 127 consecutive patients with diabetes. All patients received 1% tropicamide in both eyes. Results: There was no statistically significant difference in the amount of pupillary dilation between the three groups. Conclusion: As 2.5% phenylephrine may produce a lower incidence of side effects than the 10% concentration, we advise the use of the lower concentration, particularly among patients with diabetes, who already exhibit a higher prevalence of vascular disease and autonomic dysfunction.

Original languageEnglish
Pages (from-to)130-133
Number of pages4
JournalRetina
Volume15
Issue number2
StatePublished - May 8 1995

Fingerprint

Phenylephrine
Dilatation
Tropicamide
Vascular Diseases
Double-Blind Method
Incidence

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems

Cite this

The effects of phenylephrine 2.5% versus phenylephrine 10% on pupillary dilation in patients with diabetes. / Weiss, J. S.; Weiss, J. N.; Greenfield, David.

In: Retina, Vol. 15, No. 2, 08.05.1995, p. 130-133.

Research output: Contribution to journalArticle

@article{138a4f5996f142dbafe687a43b4c78cf,
title = "The effects of phenylephrine 2.5{\%} versus phenylephrine 10{\%} on pupillary dilation in patients with diabetes",
abstract = "Purpose: A prospective, double-blind study was conducted to compare the clinical efficacy of a combination of 1{\%} tropicamide and 2.5{\%} phenylephrine and a combination of 1{\%} tropicamide and 10{\%} phenylephrine for pupillary dilation in patients with diabetes. Methods: Either 2.5{\%} phenylephrine in one eye and 10{\%} phenylephrine in the other eye, 2.5{\%} phenylephrine in both eyes, or 10{\%} phenylephrine in both eyes was administered to 127 consecutive patients with diabetes. All patients received 1{\%} tropicamide in both eyes. Results: There was no statistically significant difference in the amount of pupillary dilation between the three groups. Conclusion: As 2.5{\%} phenylephrine may produce a lower incidence of side effects than the 10{\%} concentration, we advise the use of the lower concentration, particularly among patients with diabetes, who already exhibit a higher prevalence of vascular disease and autonomic dysfunction.",
author = "Weiss, {J. S.} and Weiss, {J. N.} and David Greenfield",
year = "1995",
month = "5",
day = "8",
language = "English",
volume = "15",
pages = "130--133",
journal = "Retina",
issn = "0275-004X",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - The effects of phenylephrine 2.5% versus phenylephrine 10% on pupillary dilation in patients with diabetes

AU - Weiss, J. S.

AU - Weiss, J. N.

AU - Greenfield, David

PY - 1995/5/8

Y1 - 1995/5/8

N2 - Purpose: A prospective, double-blind study was conducted to compare the clinical efficacy of a combination of 1% tropicamide and 2.5% phenylephrine and a combination of 1% tropicamide and 10% phenylephrine for pupillary dilation in patients with diabetes. Methods: Either 2.5% phenylephrine in one eye and 10% phenylephrine in the other eye, 2.5% phenylephrine in both eyes, or 10% phenylephrine in both eyes was administered to 127 consecutive patients with diabetes. All patients received 1% tropicamide in both eyes. Results: There was no statistically significant difference in the amount of pupillary dilation between the three groups. Conclusion: As 2.5% phenylephrine may produce a lower incidence of side effects than the 10% concentration, we advise the use of the lower concentration, particularly among patients with diabetes, who already exhibit a higher prevalence of vascular disease and autonomic dysfunction.

AB - Purpose: A prospective, double-blind study was conducted to compare the clinical efficacy of a combination of 1% tropicamide and 2.5% phenylephrine and a combination of 1% tropicamide and 10% phenylephrine for pupillary dilation in patients with diabetes. Methods: Either 2.5% phenylephrine in one eye and 10% phenylephrine in the other eye, 2.5% phenylephrine in both eyes, or 10% phenylephrine in both eyes was administered to 127 consecutive patients with diabetes. All patients received 1% tropicamide in both eyes. Results: There was no statistically significant difference in the amount of pupillary dilation between the three groups. Conclusion: As 2.5% phenylephrine may produce a lower incidence of side effects than the 10% concentration, we advise the use of the lower concentration, particularly among patients with diabetes, who already exhibit a higher prevalence of vascular disease and autonomic dysfunction.

UR - http://www.scopus.com/inward/record.url?scp=0028959685&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028959685&partnerID=8YFLogxK

M3 - Article

VL - 15

SP - 130

EP - 133

JO - Retina

JF - Retina

SN - 0275-004X

IS - 2

ER -